Redx Pharma Plc engages in drug discovery, pre-clinical development, and licensing activities in the United Kingdom. It discovers and develops small molecule drugs for treating anti-cancer and fibrosis targets in the areas of unmet medical needs. The company is developing RXC004, a porcupine inhibitor, which is in Phase I clinical development for the treatment of colorectal, pancreatic, biliary, and gastric cancers, as well as melanoma; ROCK inhibitor for treating inflammatory disease related fibrosis; ROCK2, a Rho-associated protein kinase 2 inhibitor for the treatment of diabetic nephropathy, and idiopathic pulmonary fibrosis (IPF) and non-alcoholic steatohepatitis (NASH)/liver fibrosis; and Porcupine (RXC006), a drug for IPF, NASH, and liver fibrosis. It is also developing Pan-RAF inhibitor for colorectal cancer; SHP2, a protein-tyrosine phosphatase for receptor tyrosine kinase signaling in cancer cells; and RXC005, a reversible inhibitor of Bruton's tyrosine kinase. Redx Pharma Plc has a research collaboration agreement with Jazz Pharmaceuticals plc to discover and develop drug candidates for two cancer targets in the Ras/Raf/MAP kinase pathway. The company was founded in 2010 and is based in Macclesfield, the United Kingdom.